Compare Appian Corp (APPN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Appian Corp vs TG Therapeutics Inc — how do they compare? Appian Corp trades at $35.5 (market cap $2.54B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 3× Appian Corp's market cap. Which is the better fit depends on your goals.
| APPN | TGTX | |
|---|---|---|
Market Cap | $2.54B | $7.64B |
Sector | Technology | Health |
52-Week High | $45.64 | $59.06 |
52-Week Low | $18.72 | $26.94 |
Enterprise Value | $2.67B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Appian (APPN) trades at $34.42, down 3.26% on the day, following recent earnings beats but amid broader software stock volatility. The stock shows a bullish technical trend with moving averages supporting upside, though oscillators indicate overbought conditions. Fundamentally, revenue growth remains strong with 2025 revenue at $726.94 million and a return to positive net income of $1.23 million, yet profitability metrics like ROE at -936.62% highlight ongoing challenges. Recent news highlights AI-driven partnerships and enterprise demand as key growth catalysts.
The outlook is mixed: analyst consensus is cautious with a hold-heavy rating (63.16% hold) and a $32.50 price target below the current price, signaling limited near-term upside. Risks include high debt levels, negative equity, and competitive pressures in low-code software. Investment appeal hinges on sustained AI adoption and margin improvement, but volatility and weak shareholder equity pose significant risks.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
